Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company (“Lilly”) for expanding access to Lilly’s drug, baricitinib in India. Sun Pharma will manufacture and distribute the drug in India.
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The drug is approved by the Central Drugs Standard Control Organization (CDSCO) for restricted emergency use in India.
Kirti Ganorkar, CEO-India business, Sun Pharma, said, “Through this collaboration, we aim to join our forces with Lilly to accelerate access to baricitinib in India at a time when it is most needed. This is another step by Sun Pharma towards making more treatment options available to patients in India for dealing with the pandemic.”
Source: Equity Bulls
You may also like
-
Garcinia Cambogia in Ayurveda: Kudampuli, the Sour Medicine of the Kitchen
-
First World Yogasana Championship Opens in Ahmedabad: India Pushes Yoga From Wellness Practice to Global Sport
-
Indian Surgical Robot Debuts in Kidney Transplant at PGI Chandigarh
-
Serum Institute of India to Manufacture Oxford Ebola Vaccine in Major Global Health Push
-
India’s Nanomedicine Leap: Pune Scientists Develop Gene-Silencing Platform to Target Breast Cancer Drivers
